Using computer software to assess the dose of cisplatin in cancer chemotherapy
DOI:
https://doi.org/10.18041/2390-0512/bioc..1.2756Keywords:
Cisplatin, Dose, Maximum concentration, Body surface area, Volume of distributionAbstract
A prospective, descriptive study was conducted with 20 adult patients diagnosed with cancer, treated with cisplatin, in order to assess the dosage, using the PK Curve software, which allowed estimation: half-life, maximum plasma concentration and area under the curve. The averages obtained together with the standard deviation, as described below: 13.2 years old + 50.75, 69.45 ± 18.2 kg weight, body surface area 1.76 m2 ± 0.224, 89.95 mg dose/m2 , plasma creatinine 0.93 ± 0.2 mg/dL, BUN 12.23 + 2.65 mg/dL, 11.35 + 6.02 maximum concentration µm, which was above 10 µm, the concentration at which cisplatin starts generating control cell death in in vitro studies. AUC values returned values calculated 13912.58 ± 7385.7 ng * h/mL, while the volume of distribution was 19.42 + 2,46 L and clearance of 6.56 + 0.83 L/h. Adequate correlation between body surface area and body weight, showed no parameters used to establish dose.
Downloads
References
Murillo R, Piñeros M, Wiesner C, Rivera D, Bernal L, Aguilera J, et al. Instituto Nacional de Cancerología. Plan Decenal para el Control del Cáncer en Colombia, 2012-2021 [página de internet]. 2012 Feb. [citado 2014 Agost 20]. [aprox. 3 p.]. Disponible en: http://www. cancer.gov.co/documentos/Plandecenalparaelcon- troldelcancer/PlanDecenal_Control- Cancer_2012-2021.pdf
Wang X, Grunz-Borgmann E, Parrish A. Loss of α(E)-Catenin Potentiates Cisplatin-Induced Nephrotoxicity via Increasing Apoptosis in Renal Tubular Epithelial Cells. Toxicological Sciences. 2014; 141:254-62.
Stephen D, Svetlana A, Dorothea T, Jeffrey B, Souk P, Carson L. Persistence of Cisplatin-Induced Mutagenicity in Hematopoietic Stem Cells: Implications for Secondary Cancer Risk Following Chemotherapy. Toxicological Sciences. 2014; 140:307-14.
The chemicalbookdatabase. [homepage on the Internet]. [updated 2014 Aug 23; cited 2014 Agost 12]. Available: http://www.chemicalbook. com/ProductIndex_EN.aspxand
Shaloam Dasari, Paul Bernard Tchoun wou Review. Cisplatin in cancer therapy: Molecular mechanisms of action. European Journal of Pharmacology. 2014; 740:364-78.
Ozkok A and Edelstein C. Pathophysiology of Cisplatin-Induced Acute Kidney Injury, Review. BioMed Research International; 2014.
Liub H, Zhanga Y, Hana Y, Zhaoa S, Wanga L, Zhanga Z, et al. Characterization and cytotoxicity studies of DPPC:M2+novel deliverysystem for cisplatin thermosensitivity liposome with improving loading efficiency. Colloids and Surfaces B: Biointerfaces. 2015; 131:12-20.
Drugbank. [homepage on the Internet]. Available: http://www.drugbank.ca/drugs/ DB00515
Wang MC, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2013; 369:507-16.
Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination Chemotherapy in Advanced Adrenocortical Carcinoma. N Engl J Med. 2012; 366:2189-97.
Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, et al. Improved Survival with Bevacizumab in Advanced Cervical Cancer; 2014.
GlobalRhp. [homepage on the Internet]. Available: http://www.globalrph.com/cisplatin. htm
Clarisse M, Allan P, Teresa F, Guy N, Brock C, William H. Sodium Arsenite ± Hyperthermia Sensitizes p53-Expressing Human Ovarian Cancer Cells to Cisplatin by Modulating Platinum- DNA Damage Responses. Toxicological Sciences. 2012; 127(1):139-49. Biociencias
Downloads
Published
Issue
Section
License
-
Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios<. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
-
NoComercial — No puede utilizar el material para una finalidad comercial.
-
CompartirIgual — Si remezcla, transforma o crea a partir del material, deberá difundir sus contribuciones bajo la misma licencia que el original.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
